Insights

The surefire vaccine winner following AstraZeneca’s COVID-19 trial pause

Hint: It’s not Moderna.
The post The surefire vaccine winner following AstraZeneca’s COVID-19 trial pause appeared first on Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

In auto racing, cars sometimes have to make pit stops for potential mechanical problems to be checked out. We’re seeing the equivalent of that happen now in the race to develop a coronavirus vaccine.

On Wednesday, AstraZeneca plc (NYSE: AZN) announced that it was pausing late-stage clinical trials of COVID-19 vaccine candidate AZD1222. Why? A participant in the U.K. trial experienced an unexplained illness after receiving the investigational vaccine.

The pause didn’t last long. On Saturday, AstraZeneca received a green light from U.K. regulators to resume the clinical trial. However, as pit stops do with car racing, this temporary delay changes the dynamics in the coronavirus vaccine race to some extent. And I think that there’s one surefire vaccine winner following AstraZeneca’s COVID-19 trial pause — Pfizer Inc. (NYSE: PFE).

What it doesn’t mean

Before my use of the term “surefire winner” causes a surefire firestorm, allow me to provide some context. I’m not in any way implying that Pfizer and its partner BioNTech SE (NASDAQ: BNTX) are guaranteed success with their COVID-19 vaccine candidate BNT162b2.

Granted, I think the chances of success for BNT162b2 are pretty good. I base my view on the clinical results that have been announced so far and the historical track record of vaccines that make it to phase 3 testing. Between 2006 and 2015, over 74% of vaccines in phase 3 testing went on to win FDA approval, according to industry organization BIO. But I also realize that there’s a real possibility that Pfizer’s and BioNTech’s vaccine could stumble in late-stage testing. 

I also don’t mean that Pfizer will necessarily be the best-performing stock out of all of the companies developing COVID-19 vaccines because of AstraZeneca’s delay. Smaller biotech stocks could (and probably will) deliver greater returns than Pfizer will. 

Winning the perception game

So what do I mean when I maintain that Pfizer is the “surefire winner” after AstraZeneca’s COVID-19 clinical trial pause? The big drugmaker is now viewed as the clear frontrunner in the coronavirus vaccine race by many investors. Pfizer is winning the perception game.

To be clear, I don’t think the trial pause will hurt AstraZeneca all that much over the long run. After all, it lasted only a few days. But to return to the car race analogy, AstraZeneca’s “pit stop” is allowing another drugmaker to move into a clear lead in the race.

Why isn’t Moderna Inc (NASDAQ: MRNA) that clear leader? Just a few days before AstraZeneca’s announcement of its trial pause, the biotech revealed that it’s temporarily slowing down enrollment in the late-stage study of COVID-19 vaccine candidate mRNA-1273 to boost minority participation. That’s a wise move, but the combination of Moderna’s slowdown and AstraZeneca’s delay works to Pfizer’s advantage when it comes to investors’ perception.

There are other companies with coronavirus vaccine candidates already in late-stage testing. But they’re based in China and Russia. Their vaccines are likely to be non-factors in the U.S. market. Johnson & Johnson (NYSE: JNJ) also is starting late-stage testing of its COVID-19 vaccine this month. However promising this vaccine might be, though, J&J lags well behind Pfizer.

BioNTech arguably deserves greater acclaim than Pfizer. After all, the German biotech originally developed multiple coronavirus vaccine candidates, including BNT162b2. But Pfizer recognized the potential for the BNT162 program and ponied upfront cash to fund the development of the investigational vaccines. A lot more U.S. investors know who Pfizer is than know who BioNTech is. Again, it’s all about perception.

Will Pfizer be the ultimate winner?

There’s no question in my mind that Pfizer is the clear winner from AstraZeneca’s trial delay — for now. But will the big pharma company be the ultimate winner in the coronavirus vaccine market? That remains to be seen.

I definitely think Pfizer could be the biggest winner over the long run in terms of global sales. It’s a positive sign, in my view, that the company plans to advance another COVID-19 vaccine candidate into early stage clinical testing in September. That shows that Pfizer is looking to the future and not just the near term.

But there’s also a surefire certainty: The coronavirus vaccine race is far from over.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

These 3 stocks could be the next big movers in 2020

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Keith Speights owns shares of Pfizer. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The surefire vaccine winner following AstraZeneca’s COVID-19 trial pause appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!